{"id":11492,"date":"2017-03-21T11:00:40","date_gmt":"2017-03-21T10:00:40","guid":{"rendered":"https:\/\/mileon.wordpress.com\/?p=11492"},"modified":"2017-03-21T11:00:40","modified_gmt":"2017-03-21T10:00:40","slug":"nejm-monoclonales-en-infeccion-por-clostridium-difficile-ticagrelor-en-enfermedad-arterial-periferica","status":"publish","type":"post","link":"https:\/\/www.icscyl.com\/mileon\/residentes\/2017-03-21\/nejm-monoclonales-en-infeccion-por-clostridium-difficile-ticagrelor-en-enfermedad-arterial-periferica\/","title":{"rendered":"NEJM: Monoclonales en infecci\u00f3n por Clostridium difficile, ticagrelor en enfermedad arterial perif\u00e9rica&#8230;"},"content":{"rendered":"<p><img loading=\"lazy\" decoding=\"async\" class=\" size-full wp-image-11502 alignright\" src=\"https:\/\/mileon.files.wordpress.com\/2017\/03\/nemj-1.png\" alt=\"nemj-1\" width=\"300\" height=\"225\" \/>En la sesi\u00f3n bibliogr\u00e1fica de residentes la Dra. Cuesta (R4) coment\u00f3 los siguientes art\u00edculos publicados en la revista New England Journal of Medicine:<\/p>\n<ul>\n<li>Bezlotoxumab for prevention of recurrent Clostridium difficile infection:\u00a0anticuerpos monoclonales dirigidos frente a las toxinas de Clostridium. Menos tasa de recurrencias, pero no demostr\u00f3 mayor eficacia en el tratamiento del episodio agudo. Una alternativa m\u00e1s, pero mucho m\u00e1s cara&#8230; ya veremos en que quedan los dem\u00e1s estudios que est\u00e1n por venir.<\/li>\n<li>Bariatric surgery vs intensive medical therapy for diabetes: 5 year outcomes. La cirug\u00eda bari\u00e1trica se asoci\u00f3 con mejor control gluc\u00e9mico que el tratamiento convencional. Sin embargo el estudio\u00a0presenta limitaciones como la realizaci\u00f3n en un s\u00f3lo centro, o el tama\u00f1o muestral entre otras.<\/li>\n<li>Ticagrelor vs clopidogrel in symptomatic peripheral artery disease: no se demuestra beneficio del uso de ticagrelor en esta indicaci\u00f3n comparado frente a clopidogrel. Resulta preocupante la aparici\u00f3n de disnea relacionada con el f\u00e1rmaco en el 5% de los pacientes de la rama ticagrelor.<\/li>\n<\/ul>\n<p>En el siguiente\u00a0<a href=\"https:\/\/drive.google.com\/file\/d\/0BxXYCqMXR4ZaekNSbHRuS2VsVEU\/view?usp=sharing\">enlace<\/a>\u00a0se encuentra disponible su presentaci\u00f3n.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>En la sesi\u00f3n bibliogr\u00e1fica de residentes la Dra. Cuesta (R4) coment\u00f3 los siguientes art\u00edculos publicados en la revista New England Journal of Medicine: Bezlotoxumab for prevention of recurrent Clostridium difficile infection:\u00a0anticuerpos monoclonales dirigidos frente a las toxinas de Clostridium. Menos tasa de recurrencias, pero no demostr\u00f3 mayor eficacia en el tratamiento del episodio agudo. Una [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[721],"tags":[],"class_list":["post-11492","post","type-post","status-publish","format-standard","hentry","category-residentes"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/www.icscyl.com\/mileon\/wp-json\/wp\/v2\/posts\/11492","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.icscyl.com\/mileon\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.icscyl.com\/mileon\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.icscyl.com\/mileon\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.icscyl.com\/mileon\/wp-json\/wp\/v2\/comments?post=11492"}],"version-history":[{"count":0,"href":"https:\/\/www.icscyl.com\/mileon\/wp-json\/wp\/v2\/posts\/11492\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.icscyl.com\/mileon\/wp-json\/wp\/v2\/media?parent=11492"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.icscyl.com\/mileon\/wp-json\/wp\/v2\/categories?post=11492"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.icscyl.com\/mileon\/wp-json\/wp\/v2\/tags?post=11492"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}